TIANXIN PHARMA released its first-quarter performance, with a net profit attributable to the parent company of 219 million yuan, a year-on-year increase of 48.13%
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, TIANXIN PHARMA disclosed its first-quarter report for 2025, showing that the company achieved revenue of 619 million yuan, a year-on-year increase of 25.16%; net profit attributable to the parent company was 219 million yuan, a year-on-year increase of 48.13%; and net profit excluding non-recurring gains and losses was 209 million yuan, a year-on-year increase of 53.30%. The basic earnings per share were 0.50 yuan
According to the Zhitong Finance APP, TIANXIN PHARMA (603235.SH) disclosed its first-quarter report for 2025, reporting revenue of 619 million yuan, a year-on-year increase of 25.16%; net profit attributable to shareholders of 219 million yuan, a year-on-year increase of 48.13%; and net profit excluding non-recurring items of 209 million yuan, a year-on-year increase of 53.30%. Basic earnings per share are 0.50 yuan